Competition of drugs to serum albumin in combination therapy.

Article Details

Citation

Copy to clipboard

Sulkowska A, Bojko B, Rownicka J, Sulkowski W

Competition of drugs to serum albumin in combination therapy.

Biopolymers. 2004 Jun 15;74(3):256-62.

PubMed ID

15150801 [ View in PubMed

]

Abstract

The mechanism of cooperative binding of both cytarabine and fluorouracil, used in combination therapy, to the transporting protein [bovine serum albumin (BSA)] has been investigated. Present study shows a strategy of estimating the kind of competition between these drugs with the use of uv and NMR spectroscopy. Two mechanisms of the competition to the transporting protein are proposed. For the quantitative investigations the effect of the protein on both the line width and chemical shifts of the NMR signals of the 5-fluorouracil and cytarabine was analyzed. The pi-pi interaction between the pyrimidine ring of the drugs and the aromatic residues of the protein has been postulated. The binding site for both 5-fluorouracil and cytarabine on BSA was found to be situated in the hydrophobic IIA subdomain. The competition of these two drugs and the removal of 5-fluorouracil by cytarabine from the common binding site in serum albumin tertiary structure are observed.

DrugBank Data that Cites this Article

Drug Carriers

Drug	Carrier	Kind	Organism	Pharmacological Action	Actions
Fluorouracil	Serum albumin	Protein	Humans	No	Not Available	Details